Com­mer­cial-stage man­u­fac­tur­ing key for CD­MOs as biotech fund­ing pull­back con­tin­ues, Fu­ji­film Diosynth CEO says

On the back of re­duced fund­ing in ear­ly clin­i­cal-stage as­sets, CD­MOs need to strength­en their com­mer­cial, large-scale man­u­fac­tur­ing ca­pa­bil­i­ties for 2024 in what looks like an­oth­er chal­leng­ing year for man­u­fac­tur­ers, Fu­ji­film Diosynth CEO Lars Pe­tersen said.

“I think the biggest hur­dle is how to ad­just to the slow­down of ven­ture cap­i­tal­ists fund­ing star­tups. It will come back, but when it’ll come back — no­body knows,” Pe­tersen told End­points News in an in­ter­view. “[Fu­ji­film Diosynth] es­pe­cial­ly sees large-scale com­mer­cial boom­ing, there is still a huge de­mand…and it’s of­ten from com­pa­nies who al­ready have a rev­enue, and they don’t nec­es­sar­i­ly need a lot of ven­ture cap­i­tal­ist fund­ing,” he ex­plained.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER